Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.57 |
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | DRD3 | P35462 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.55 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8311608 | 0.74 | MAPT (0.62) | DRD4DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL11000972 | 0.74 | DRD4 (0.53) | DRD4DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL1442567 | 0.73 | DRD2 (1.00) | DRD4DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL4138314 | 0.73 | NR3C1 (0.66) | DRD4DRD2DRD3TSHRMEN1 | |
| SCHEMBL10650805 | 0.73 | DRD4 (0.49) | DRD4DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL16652492 | 0.72 | MAPT (0.69) | DRD4DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL10998482 | 0.72 | KMT2A (0.53) | DRD4DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL24393208 | 0.72 | MAPT (1.00) | ALDH1A1MAPTKDM4CTSHRHTT | |
| SCHEMBL4813164 | 0.71 | ALDH1A1 (1.00) | DRD4DRD2DRD3ALDH1A1TRPC5 | |
| SCHEMBL4519472 | 0.71 | DRD4 (0.62) | DRD4DRD2DRD3MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328886-B1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PF MEDICAMENT (FR) | 2016-12-28 | — | — | EP | disclosed |
| US-8618287-B2 | Derivatives of triazines and uracils, their preparation and their application in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2013-12-31 | — | — | US | disclosed |
| EP-2328886-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | Pierre Fabre Médicament (FR) | 2011-06-08 | — | — | EP | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | UNG, TYMS, UMPS | DRD4 750/4885DRD2 1331/4885DRD3 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.